{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:25:06Z","timestamp":1759778706017},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00347-018-0720-2","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T16:58:27Z","timestamp":1527008307000},"page":"456-463","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Studien\u00fcberblick zur Fr\u00fchgeborenenretinopathie"],"prefix":"10.1007","volume":"115","author":[{"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"issue":"2","key":"720_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C (2008) Retinopathy of prematurity: a\u00a0global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77\u201382","journal-title":"Early Hum Dev"},{"issue":"2","key":"720_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1990) Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 108(2):195\u2013204","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"720_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00347-008-1841-9","volume":"105","author":"C Jandeck","year":"2008","unstructured":"Jandeck C, Kellner U, Lorenz B, Seiberth V (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105(10):955\u2013963","journal-title":"Ophthalmologe"},{"issue":"12","key":"720_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"720_CR5","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group (2004) Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233\u2013248 (discussion 248\u201350)","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"720_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0301-4738.29505","volume":"55","author":"PK Shah","year":"2007","unstructured":"Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55(1):75\u201376","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"720_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE et\u00a0al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38(3):233\u2013237","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"8","key":"720_CR8","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1111\/aos.13069","volume":"94","author":"JM Walz","year":"2016","unstructured":"Walz JM, Bemme S, Pielen A, Aisenbrey S, Breu\u00df H, Alex AF et\u00a0al (2016) The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol 94(8):e744\u2013e752","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"720_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","volume":"94","author":"K Matsuyama","year":"2010","unstructured":"Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94(9):1215\u20131218","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"720_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327\u2013333.e1","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"720_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong YR, Kim YH, Kim SY, Nam GY, Cheon HJ, Lee SJ (2015) Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina 35(9):1772\u20131777","journal-title":"Retina"},{"issue":"7","key":"720_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"5","key":"720_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5\u2011year retrospective analysis. Ophthalmology 122(5):1008\u20131015","journal-title":"Ophthalmology"},{"issue":"3","key":"720_CR14","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C et\u00a0al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101(3):365\u2013370","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"720_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA et\u00a0al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a\u00a0randomized clinical trial. JAMA Ophthalmol 132(11):1327\u20131333","journal-title":"JAMA Ophthalmol."},{"key":"720_CR16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard M\u2011N et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4). https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"issue":"1","key":"720_CR17","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu M\u2011H, Hsu K\u2011H, Liao P\u2011J, Chen Y\u2011P, Lai C\u2011C et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11(1):e148019","journal-title":"PLoS ONE"},{"issue":"5","key":"720_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3928\/23258160-20160419-16","volume":"47","author":"KL Tawse","year":"2016","unstructured":"Tawse KL, Jeng-Miller KW, Baumal CR (2016) Current practice patterns for treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 47(5):491\u2013495","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"issue":"6","key":"720_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/aos.12266","volume":"92","author":"BC Harder","year":"2014","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC (2014) Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 92(6):577\u2013581","journal-title":"Acta Ophthalmol"},{"issue":"30","key":"720_CR20","first-page":"e20","volume":"52","author":"AJ Connor","year":"2015","unstructured":"Connor AJ, Papastavrou VT, Hillier RJ, Shafiq A (2015) Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity. J\u00a0Pediatr Ophthalmol Strabismus 52(30):e20\u2013e21","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"6","key":"720_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR et\u00a0al (2017) Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol 135(6):654\u2013656","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"720_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00347-013-2932-9","volume":"111","author":"TU Krohne","year":"2014","unstructured":"Krohne TU, Holz FG, Meyer CH (2014) Pharmacokinetics of intravitreally administered VEGF inhibitors. Ophthalmologe 111(2):113\u2013120","journal-title":"Ophthalmologe"},{"key":"720_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S et al (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr."},{"issue":"1","key":"720_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol 254(1):31\u201336","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"720_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ (2013) Exudative retinopathy and detachment: a\u00a0late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J\u00a0AAPOS 17(3):323\u2013325","journal-title":"J. AAPOS"},{"issue":"3","key":"720_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47(3):280\u2013283","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"issue":"3","key":"720_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3928\/23258160-20170301-10","volume":"48","author":"AR Hajrasouliha","year":"2017","unstructured":"Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48(3):255\u2013259","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"issue":"5","key":"720_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5935\/0004-2749.20150079","volume":"78","author":"M Gunay","year":"2015","unstructured":"Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F (2015) Evaluation of 2\u2011year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 78(5):300\u2013304","journal-title":"Arq Bras Oftalmol"},{"key":"720_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","volume":"22","author":"SD Nicoar\u0103","year":"2016","unstructured":"Nicoar\u0103 SD, \u015etef\u0103nu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8\u2011year retrospective analysis. Med Sci Monit 22:1192\u20131209","journal-title":"Med Sci Monit"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0720-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T09:47:43Z","timestamp":1571392063000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0720-2"}},"subtitle":["Aktueller Wissensstand und Ausblick"],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0720-2","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"22 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Stahl weist auf Unterst\u00fctzung durch folgende Firmen hin: Allergan, Bayer, Boehringer Ingelheim, Novartis, Orphan Europe.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}